42 results
8-K
EX-99.1
LBPH
Longboard Pharmaceuticals Inc
10 Jun 24
Regulation FD Disclosure
9:05am
-label, long-term safety study of bexicaserin in participants with a range of DEEs, including Dravet syndrome (n=3), Lennox-Gastaut syndrome (n=20
8-K
LBPH
Longboard Pharmaceuticals Inc
10 Jun 24
Regulation FD Disclosure
9:05am
and Epileptic Encephalopathies ("DEEs").
The PACIFIC OLE Study is a 52-week Phase 2, open-label, long-term safety study of bexicaserin in participants
8-K
EX-99.1
LBPH
Longboard Pharmaceuticals Inc
2 May 24
Longboard Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Updates
4:10pm
-term investments
Prepaid expenses and other current assets
Total current assets
Right-of-use assets
Property and equipment
Other long-term assets
PRE 14A
scdc6e
28 Mar 24
Preliminary proxy
4:36pm
8-K
EX-99.1
k5eo4o4fphp2t8trjllx
12 Mar 24
Longboard Pharmaceuticals Reports Full Year 2023 Financial Results and Provides Corporate Updates
4:10pm
424B5
la5afnabde7koli qn
4 Jan 24
Prospectus supplement for primary offering
4:48pm
424B5
pqg fxgeldniq
2 Jan 24
Prospectus supplement for primary offering
4:54pm
8-K
EX-99.1
31sbvcbubvbg8lm
29 Nov 23
Regulation FD Disclosure
8:35am
8-K
EX-99.1
efbxbd9o79wvrt5obx
2 Nov 23
Longboard Pharmaceuticals Provides Corporate Update and Reports Third Quarter 2023 Financial Results
4:05pm
8-K
EX-99.1
6yu mdgbtqq7uy8
11 Oct 23
Regulation FD Disclosure
9:26am
8-K
EX-99.1
fs78r h16nxnd6kgh4ci
23 Aug 23
Enrolled 52 participants with Developmental and Epileptic Encephalopathies (DEEs) into the PACIFIC Study
8:46am
424B5
ab3g159f4nufe7hwk yj
4 Aug 23
Prospectus supplement for primary offering
4:20pm
8-K
EX-99.1
z3i3gy x10xjp
3 Aug 23
Longboard Pharmaceuticals Provides Corporate Update and Reports Second Quarter 2023 Financial Results
4:12pm
8-K
EX-99.1
y5b55inyl
9 May 23
Longboard Pharmaceuticals Provides Corporate Update and Reports First Quarter 2023 Financial Results
4:06pm